CA2176927A1 - Transparent liquid for encapsulated drug delivery - Google Patents

Transparent liquid for encapsulated drug delivery

Info

Publication number
CA2176927A1
CA2176927A1 CA002176927A CA2176927A CA2176927A1 CA 2176927 A1 CA2176927 A1 CA 2176927A1 CA 002176927 A CA002176927 A CA 002176927A CA 2176927 A CA2176927 A CA 2176927A CA 2176927 A1 CA2176927 A1 CA 2176927A1
Authority
CA
Canada
Prior art keywords
delivery composition
drug delivery
weight percent
encapsulated drug
plasticizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002176927A
Other languages
French (fr)
Other versions
CA2176927C (en
Inventor
Seang H. Yiv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athena Neurosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2176927A1 publication Critical patent/CA2176927A1/en
Application granted granted Critical
Publication of CA2176927C publication Critical patent/CA2176927C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

There is provided a stable transparent multi-component composition useful for the delivery of water soluble active agents to animals.
The compositions are formulated with a mixture of an oil phase, an aqueous phase, and a surfactant system along with the active agent to be delivered to the animal. The compositions are specially formulated to be compatible with capsules such as gelatin and starch capsules.
The aqueous phase of tile compositions contains a substantial amount of polyethylene glycol and can optionally also contain a plasticizer.
Preferred active agents are proteinaceous materials.

Claims (39)

1. A stable, transparent drug delivery composition.
suitable for storage and administration of biologically active materials, comprising:
(a) a delivery composition comprising:
(1) from about 1 to about 80 weight percent of a pharmaceutically acceptable oil phase;
(2) from about 3 to about 93 weight percent surfactant;
(3) from about 2 to about 60 weight percent polyethylene glycol;
(4) from about 0.5 to about 15 weight percent water; and (b) a therapeutically effective amount of a biologically active material having an octanol:water partition coefficient of less than about 0.1;
provided that the composition does not contain a mixture of cholesterol and phospholipid, and wherein the ratio of the polyethylene glycol to water is at least 2:1.
2. The drug delivery composition of claim 1 wherein the delivery composition further comprises at least one plasticizer comprising sorbitol, mannitol, glycerin, sucrose, fructose, glucose, or lactose, said plasticizer being present in an amount of from about 0.5 to about 10 weight percent of the delivery composition.
3. The drug delivery composition of claim 2 wherein the drug delivery composition is contained in a capsule and the ratio of the polyethylene glycol to water is from about 4:1 to about 99:1, and said plasticizer comprises sorbitol, mannitol, or glycerin.
4. The encapsulated drug delivery composition of claim 3 wherein the capsule is a gelatin or starch capsule
5. The encapsulated drug delivery composition of claim 4 wherein the active material comprises a protein, peptide, or polysaccharide.
6. The encapsulated drug delivery composition of claim 5 wherein the surfactant component is a mixture of surfactants comprising a low HLB surfactant, said low HLB
surfactant having an HLB below 10 and a high HLB surfactant, said high HLB surfactant having an HLB above 10, and wherein the low HLB surfactant comprises a C9-13 monoglyceride.
7. The encapsulated drug delivery composition of claim 5 wherein the active material comprises a medicament which is selected from the group consisting of erythropoietin, insulin, a growth hormone, calcitonin, growth colony stimulating factors, RGD peptides, hematoregulatory peptides, collagenase inhibitors, angiotensin inhibitors, heparins, hypothalamic releasing peptides, tissue plaminogen activators, artial natriuretic peptides, tumor necrosis factor, cyclosporine, vasopressin, a vasopressin antagonist, t-PA, vamprire bat plasminogen amplifier, urokinase, streptokinase, interferon and interleukin, in a biologically effective, therapeutic, non-toxic quantity .
8. The encapsulated drug delivery composition of claim 5 wherein the active material comprises a medicament which is selected from the group consisting of insulins, growth hormones, fibrinogen antagonists and calcitonins.
9. A stable, transparent delivery composition, comprising:
(a) from about 5 to about 70 weight percent of a pharmaceutically acceptable oil phase;
(b) from about 10 to about 80 weight percent surfactant;

(c) from about 5 to about 60 weight percent of an aqueous phase comprising from about 60 to about 95 weight percent polyethylene glycol, from about 2 to about 30 weight percent water, and from about 1 to about 15 weight percent plasticizer comprising sorbitol, mannitol, glycerin, sucrose, fructose, glucose, or lactose; and wherein the ratio of the polyethylene glycol to water is at least 2:1, provided that the composition does not contain a mixture of cholesterol and phospholipid.
10. The delivery composition of claim 9 wherein the polyethylene glycol to water ratio is from about 4:1 to about 99:1, and said plasticizer comprises sorbitol, mannitol, or glycerin.
11. The delivery composition of claim 10 wherein the aqueous phase consists of said water, polyethylene glycol, and plasticizer.
12. The delivery composition of claim 11 further comprising a therapeutically effective amount of a biologically active, therapeutic material having an octanol:water partition coefficient of less than 0.1.
13. The drug delivery composition of claim 12 wherein the drug delivery composition is contained in a hard gelatin, soft gelatin, or starch capsule.
14. The encapsulated drug delivery composition of claim 13 wherein the biologically active material comprises a protein, peptide, or polysaccharide.
15. The encapsulated drug delivery composition of claim 14 wherein the surfactant component is a mixture of surfactants comprising a low HLB surfactant, said low HLB
surfactant having an HLB below 10 and a high HLB surfactant, said high HLB surfactant having an HLB above 10, and wherein the low HLB surfactant comprises a C9-13 monoglyceride.
16. The encapsulated drug delivery composition of claim 14 wherein the active material comprises a medicament which is selected from the group consisting of erythropoietin, insulin, a growth hormone, calcitonin, growth colony stimulating factors, RGD peptides, hematoregulatory peptides, collagenase inhibitors, angiotensin inhibitors, heparins, hypothalamic releasing peptides, tissue plaminogen activators, artial natriuretic peptides, tumor necrosis factor, cyclosporine, vasopressin, a vasopressin antagonist, t-PA, vamprire bat plasminogen amplifier, urokinase, streptokinase, interferon and interleukin, in a biologically effective, therapeutic, non-toxic quantity.
17. The encapsulated drug delivery composition of claim 14 wherein the active material comprises a medicament which is selected from the group consisting of insulins, growth hormones, fibrinogen antagonists and calcitonins .
18. The encapsulated drug delivery composition of claim 14 wherein the oil is selected from the group consisting of triglycerides having from 18 to 81 carbon atoms and propylene glycol diesters having from 7 to 55 carbon atoms.
19. A method of administering an encapsulated drug delivery composition, comprising:
providing a capsule within which is contained a drug delivery composition comprising:
(a) a delivery composition comprising:
(1) from about 5 to about 70 weight percent of an oil phase;
(2) from about 5 to about 60 weight percent of an aqueous phase consisting essentially of water, polyethylene glycol, and at least one plasticizer, said aqueous phase comprising from about 2 to about 30 weight percent water, from about 50 and 95 weight percent polyethylene glycol, and from about 1 to about 15 weight percent plasticizer comprising sorbitol, mannitol, glycerin, sucrose, fructose, glucose, or lactose;
(3) from about 15 to about 75 weight percent of a surfactant mixture; and (b) a therapeutically effective amount of a biologically active therapeutic material having an octanol:water partition coefficient of less than about 0.1;
and provided that the delivery composition does not contain a mixture of cholesterol and phospholipid; and administering said encapsulated drug delivery composition either orally, rectally, or vaginally to the body of an animal.
20. The method of claim 19 wherein said active material is either a protein, peptide, or polysaccharide and said plasticizer comprises sorbitol, mannitol, or glycerin.
21. The method of claim 20 wherein said administration is oral.
22. The method of claim 21 wherein the weight ratio of polyethylene glycol to water in said delivery composition is from 4:1 to 99:1.
23. The encapsulated drug delivery composition of claim 6 wherein said low HLB surfactant is present in an amount of from about 10 to about 40 weight percent of said delivery composition and said high HLB surfactant is present in an amount of from about 10 to about 40 weight percent of said delivery composition.
24. The encapsulated drug delivery composition of claim 23 wherein said delivery composition comprises from about 15 to about 55 weight percent polyethylene glycol.
25. The encapsulated drug delivery composition of claim 5 wherein said surfactant mixture comprises from 15 to 75 weight percent of said delivery composition.
26. The encapsulated drug delivery composition of claim 25 provided that said plasticizer does not comprise propylene glycol.
27. The encapsulated drug delivery composition of claim 7 provided that said plasticizer does not comprise propylene glycol.
28. The encapsulated drug delivery composition of claim 24 provided that said plasticizer does not comprise propylene glycol.
29. The encapsulated drug delivery composition of claim 15 wherein said low HLB surfactant is present in an amount of from about 10 to about 40 weight percent of said delivery composition and said high HLB surfactant is present in an amount of from about 10 to about 40 weight percent of said delivery composition.
30. The encapsulated drug delivery composition of claim 29 wherein said aqueous phase comprises from about 70 to about 90 weight percent polyethylene glycol, and the ratio of the polyethylene glycol to water is from about 5:1 to about 95:5.
31. The encapsulated drug delivery composition of claim 14 provided that said plasticizer does not comprise propylene glycol.
32. The encapsulated drug delivery composition of claim 16 provided that said plasticizer does not comprise propylene glycol.
33. The encapsulated drug delivery composition of claim 29 provided that said plasticizer does not comprise propylene glycol.
34. The method of claim 22 wherein the surfactant component of said delivery composition is a mixture of surfactants comprising a low HLB surfactant, said low HLB
surfactant having an HLB below 10 and a high HLB surfactant, said high HLB surfactant having an HLB above 10, and wherein the low HLB surfactant comprises a C9-13 monoglyceride.
35. The method of claim 34 wherein said low HLB
surfactant is present in an amount of from about 10 to about 40 weight percent of said delivery composition and said high HLB surfactant is present in an amount of from about 10 to about 40 weight percent of said delivery composition.
36. The method of claim 35 wherein the active material comprises a medicament which is selected from the group consisting of erythropoietin, insulin, a growth hormone, calcitonin, growth colony stimulating factors, RGD
peptides, hematoregulatory peptides, collagenase inhibitors, angiotensin inhibitors, heparins, hypothalamic releasing peptides, tissue plaminogen activators, artial natriuretic peptides, tumor necrosis factor, cyclosporine, vasopressin, a vasopressin antagonist, t-PA, vamprire bat plasminogen amplifier, urokinase, streptokinase, interferon and interleukin, in a biologically effective, therapeutic, non-toxic quantity.
37. The method of claim 35 wherein the drug delivery composition is contained in a hard gelatin, soft gelatin, or starch capsule.
38. The method of claim 22 provided that said plasticizer does not comprise propylene glycol.
39. The method of claim 35 provided that said plasticizer does not comprise propylene glycol.
CA2176927A 1993-11-17 1994-11-16 Transparent liquid for encapsulated drug delivery Expired - Lifetime CA2176927C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15384693A 1993-11-17 1993-11-17
US08/153,846 1993-11-17
PCT/US1994/013394 WO1995014037A1 (en) 1993-11-17 1994-11-16 Transparent liquid for encapsulated drug delivery

Publications (2)

Publication Number Publication Date
CA2176927A1 true CA2176927A1 (en) 1995-05-26
CA2176927C CA2176927C (en) 2010-03-23

Family

ID=22548991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2176927A Expired - Lifetime CA2176927C (en) 1993-11-17 1994-11-16 Transparent liquid for encapsulated drug delivery

Country Status (8)

Country Link
US (1) US5707648A (en)
EP (1) EP0736041B1 (en)
JP (3) JPH09510182A (en)
AT (1) ATE317397T1 (en)
AU (1) AU692506B2 (en)
CA (1) CA2176927C (en)
DE (1) DE69434626D1 (en)
WO (1) WO1995014037A1 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352707B1 (en) 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB2318056B (en) * 1995-08-08 1999-05-26 Danbiosyst Uk Composition for enhanced uptake of polar drugs from the colon
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
ZA9711731B (en) 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
FR2761889B1 (en) * 1997-04-11 1999-12-31 Oreal PHARMACEUTICAL, COSMETIC OR DERMO-PHARMACEUTICAL PATCH FOR THE DELIVERY OF SEVERAL ACTIVE COMPOUNDS OF DIFFERENT NATURE
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
AU731909B2 (en) * 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
ATE267613T1 (en) * 1998-03-05 2004-06-15 Phares Pharm Res Nv MEDICINAL PRODUCTS AND THEIR USE
CA2329252A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
AU745880B2 (en) 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
JP2000237284A (en) * 1999-02-17 2000-09-05 Shionogi Qualicaps Kk Phermaceutical preparation in hard capsule
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19913692A1 (en) * 1999-03-25 2000-09-28 Basf Ag Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances
US6228392B1 (en) * 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DE10026699A1 (en) * 2000-05-30 2001-12-06 Basf Ag Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
DE60115433T2 (en) 2000-05-31 2006-08-03 Encelle, Inc. METHOD FOR THE TREATMENT OF CHRONIC DISEASES
US6582682B2 (en) * 2000-10-30 2003-06-24 Noville, Inc. Oral care compositions comprising stabilized chlorine dioxide
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
ES2290095T3 (en) * 2000-12-27 2008-02-16 Ares Trading S.A. LIPID MICROPARTICLES BY CRIOGENIC MICRONIZATION.
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
MXPA04003640A (en) * 2001-10-16 2005-04-11 Rxkinetix Inc High-concentration protein formulations and method of manufacture.
ATE424815T1 (en) * 2001-12-03 2009-03-15 Dor Biopharma Inc STABILIZED REVERSE MICELLAR COMPOSITIONS AND USE THEREOF
JP4624678B2 (en) 2002-02-21 2011-02-02 パイオニア・サージカル・オーソバイオロジックス，インコーポレイテッド Cross-linked bioactive hydrogel matrix
US20080086792A1 (en) 2006-10-13 2008-04-17 Thomas Charles Kuracina Method and apparatus for diverting sweat, liquid, moisture or the like from an eye
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7291501B2 (en) 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
US7445933B2 (en) * 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
ATE493973T1 (en) 2004-06-04 2011-01-15 Teva Pharma PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US20060205904A1 (en) * 2005-03-11 2006-09-14 St Clair David J Oil gels of controlled distribution block copolymers and ester oils
CA2648594C (en) * 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
RU2472539C2 (en) 2007-08-06 2013-01-20 Аллерган, Инк. Methods and devices for desmopressin preparation delivery
MX2010003979A (en) * 2007-10-16 2010-06-02 Biocon Ltd An orally administerable solid pharmaceutical composition and a process thereof.
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US20110065632A1 (en) * 2008-05-14 2011-03-17 Zheng Xin Dong Pharmaceutical compositions of somatostatin-dopamine conjugates
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
LT3225249T (en) * 2008-05-21 2019-01-10 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009008094A1 (en) * 2009-02-09 2010-08-19 Barnikol-Keuten, Doris, Dr. In situ adhesive gel-forming preparations, in particular for topical application to moisturized skin / mucosa
TWI480286B (en) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd Composition and drug delivery of bisphosphonates
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI471321B (en) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
KR101792696B1 (en) 2009-06-18 2017-11-02 알레간 인코포레이티드 Safe desmopressin administration
JP2011068636A (en) * 2009-07-30 2011-04-07 Kowa Co Liquid-filled capsule
WO2011079127A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
MX354988B (en) 2011-10-25 2018-03-28 Prothena Biosciences Ltd Antibody formulations and methods.
JP2014532713A (en) 2011-11-02 2014-12-08 ハルシオン，インコーポレイテッド Wound treatment methods and compositions
US9668474B2 (en) * 2012-02-10 2017-06-06 Stepan Company Structured surfactant suspending systems
CN104768565B (en) 2012-11-01 2017-04-26 益普生制药股份有限公司 Somatostatin analogs and dimers thereof
TWI523863B (en) 2012-11-01 2016-03-01 艾普森藥品公司 Somatostatin-dopamine chimeric analogs
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
JP7211704B2 (en) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス A tablet containing a GLP-1 agonist and an enteric coating
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237814A1 (en) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. WATER-FREE EMULSIONS AND USE THEREOF
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
CA1301642C (en) * 1987-03-30 1992-05-26 Howard Bernard Dawson Chemical formulations
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
US5230185A (en) * 1990-04-06 1993-07-27 Church & Dwight Co., Inc. Blasting apparatus and method
US5045337A (en) * 1990-04-19 1991-09-03 The Procter & Gamble Company Food microemulsion
EP0580778B1 (en) * 1991-04-19 1999-08-11 LDS Technologies, Inc. Convertible microemulsion formulations
EP0597007B1 (en) * 1991-07-26 1996-10-16 Smithkline Beecham Corporation W/o microemulsions
WO1993006921A1 (en) * 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
AU2881392A (en) * 1991-11-15 1993-06-15 Klaus Kleinhoff Spoked wheel, wheel rim and spoke nipple for spoked wheels, as well as process for producing spoked wheel rims
US5177911A (en) * 1991-11-15 1993-01-12 Ruemelin Charles R Abrasive blast cabinet
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
EP0684834A4 (en) * 1993-02-17 1996-09-25 Smithkline Beecham Corp Microemulsions comprising therapeutic peptides.
WO1994019000A1 (en) * 1993-02-17 1994-09-01 Smithkline Beecham Corporation Microemulsions containing pharmaceutical compositions
JPH08507066A (en) * 1993-02-17 1996-07-30 スミスクライン・ビーチャム・コーポレイション Microemulsions containing therapeutic peptides

Also Published As

Publication number Publication date
JP2008101017A (en) 2008-05-01
CA2176927C (en) 2010-03-23
AU1291795A (en) 1995-06-06
DE69434626D1 (en) 2006-04-20
ATE317397T1 (en) 2006-02-15
WO1995014037A1 (en) 1995-05-26
JPH09510182A (en) 1997-10-14
JP5100334B2 (en) 2012-12-19
EP0736041B1 (en) 2006-02-08
EP0736041A4 (en) 1997-09-10
US5707648A (en) 1998-01-13
EP0736041A1 (en) 1996-10-09
AU692506B2 (en) 1998-06-11
JP2012149074A (en) 2012-08-09

Similar Documents

Publication Publication Date Title
CA2176927A1 (en) Transparent liquid for encapsulated drug delivery
US5719122A (en) Pharmaceutical compositions containing a calcitonin
US4617149A (en) Growth hormone release factor analogs
Cleland et al. Formulation and delivery of proteins and peptides: design and development strategies
US5350741A (en) Enteric formulations of physiologically active peptides and proteins
US6558695B2 (en) Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
AU617157B2 (en) Intravaginal delivery of biologically active polypeptides
US5183802A (en) Pharmaceutical compositions for intranasal administration of calcitonin
JP2002515449A5 (en)
US5968899A (en) Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
EA200501001A1 (en) PHARMACEUTICAL COMPOSITION WITH INSOLVABLE ACTIVE AGENT
EP0387352A1 (en) Enteric formulations of physiologically active peptides and proteins.
JPH026405A (en) Composition for transmission of a medicine via lungs
EP0206947A2 (en) Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption
US4954342A (en) Pharmaceutical composition for intrarectal administration of a calcitonin and unit dosage forms prepared therefrom
NZ215730A (en) Sustained-release peptide compositions containing proteins as carriers
JPH04247026A (en) Oral agent disintegrating in lower part of digestive tract
US5011824A (en) Rectal motilin preparation
JPH0859503A (en) Liposome preparation for administering pepide or protein medicine through mouth or mucosa
US4973579A (en) Enhancment of absorption of drugs from gastrointestinal tract using choline ester salts
WO1993006854A1 (en) Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl
WO2000033816A1 (en) Formulation for delivery of particulate material to mucosal membranes
JPH07507565A (en) Pharmaceutical compositions containing nonionic surfactants
KR20000051004A (en) Hyaluronate microparticles for sustained release of a protein drug
WO1996012493A1 (en) Absorption enhancer/solubilizer combination for improved bioavailability of a zwitterionic compound

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141117